Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Treatment With pMDI Ensifentrine Found to Improve Lung Function

Seven days of treatment with ensifentrine, given using a pressurized metered-dose inhaler — called a pMDI — resulted in marked lung function improvements in people with moderate to severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 2 clinical trial. “This study demonstrates that ensifentrine administered…

MUC5AC Protein May Help Cause Thick, Sticky Mucus in Lungs

A mucus protein called MUC5AC may contribute to the abnormally thick and sticky mucus that develops in people with respiratory diseases such as chronic obstructive pulmonary disease (COPD), a new study shows. “MUC5AC seems to be crucial to the formation of stagnant, thicker mucus we see in pulmonary…

Zephyr Valve Now Covered By 2 More Blue Cross Blue Shield Plans

Two additional Blue Cross Blue Shield (BCBS) plans are now covering Pulmonx’s Zephyr Endobronchial Valve and similar devices to treat severe emphysema, a form of chronic obstructive pulmonary disease (COPD). With the addition of these two plans to similar previous policy decisions, valves will be now covered for the…

Renovion, COPD Foundation Partner on New Therapy to Clear Mucus

Renovion is teaming up with the COPD Foundation to develop a new nebulized therapy that aims to help clear mucus and reduce inflammation in people with chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis. Phase 2 clinical trials of the investigational treatment, called  ARINA-1, are planned to…

NIH Renews Grant to Research Mechanisms of COPD and IPF

A $12.8 million five-year renewal grant from the National Institutes of Health (NIH) will fund research that seeks to better understand the molecular mechanisms that drive chronic obstructive pulmonary disease (COPD) and other lung diseases. The research also aims to increase understanding of how cigarette smoking affects the development…

Platelet-based Therapy May Slow Lung Function Decline

Treatment with PRP-PC, an investigational platelet-based cellular therapy, may slow the decline in lung function typically experienced by people with chronic obstructive pulmonary disease (COPD), a new study with real-world data indicates. With this therapy, being developed by H-CYTE, a person’s own blood is treated in the lab…